cyrilzakka/clinical-trials huggingface dataset:
To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer

Through the implementation of prospective, multi-center, single-group target value research to verify the safety and effectiveness of the microwave ablation treatment system for the ablation treatment of primary liver cancer.

The safety and effectiveness of the microwave ablation treatment system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. for the ablation treatment of primary liver cancer is verified through the implementation of prospective, multi-center, single-group target value research. According to the requirements of the trial, 139 patients who were diagnosed with primary liver cancer before surgery and met the inclusion criteria without any exclusion criteria were selected for treatment of their liver cancer with a microwave ablation treatment system, 1 month, 3 months and 6 months after surgery Carry out clinical and imaging follow-up to evaluate the safety of the operation and the effect of tumor ablation.

Eligibility Criteria:
Inclusion Criteria:

* Pathological and/or clinical diagnosis confirmed as primary liver cancer (hepatocellular carcinoma).
* Single tumor with maximum diameter ≤ 5cm ; or tumors number ≤ 3 with maximum diameter ≤ 3cm.
* No invasion of blood vessels, gallbladder, adjacent organs and distant metastasis.
* Child-Pugh class A or B classification, or meet the standard after treatment.
* Able to understand the content of clinical trials, voluntarily participate in the trial and sign informed consent.

Exclusion Criteria:

* Pregnant or breastfeeding, or preparing to become pregnant during the trial.
* Participating in clinical trials of other devices or drugs.
* Uncorrectable coagulation dysfunction (after corrective treatment, the PT exceeds the normal control value by more than 3s).
* PLT \<50x109/L.
* Intractable massive ascites.
* Cachexia.
* MRI examination is contraindicated or the investigator judges it is not suitable for MRI examination.
* Patients with bleeding from esophageal (fundus of stomach) varicose veins 1 month before surgery.
* Patients with impaired consciousness or unable to cooperate with treatment.
* The investigator judged that it is not suitable to participate in clinical trials.
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade (standard of care) vary in adults with Marfan syndrome. However, aortic stiffness is often present, and can be a predictor of aortic dilation and cardiovascular complications. In addition, adults with Marfan syndrome develop left ventricular diastolic dysfunction, which can progress to heart failure. Aortic stiffness and diastolic dysfunction are important and logical therapeutic targets in adults with Marfan syndrome.

TGF-beta mediates disease pathogenesis in Marfan syndrome and contributes to aortic stiffness. The angiotensin receptor blocker, losartan, inhibits TGF-beta activity and reverses aortic wall pathology in a Marfan mouse model. Losartan also decreases aortic stiffness and improves diastolic function in hypertension, renal disease and hypertrophic cardiomyopathy.

This trial is a randomized, double-blind trial of 50 adults with Marfan syndrome, treated with 6 months of atenolol vs. losartan. Arterial tonometry for aortic stiffness and echocardiography for diastolic function will be performed at the beginning and end of treatment. A blood draw for serum markers of extracellular matrix turnover and inflammation will also be performed at 0 and 6 months. We plan to determine whether losartan decreases aortic stiffness and left ventricular diastolic dysfunction significantly more than atenolol.

Please See Summary.

Eligibility Criteria:
Inclusion Criteria:

* Age greater than 25 years
* Clinical Marfan Syndrome

Exclusion Criteria:

* Previous aortic or cardiac surgery
* Pregnancy
* Renal Insufficiency
* Medication intolerance
The Effect of the Copenhagen Adduction Exercise on Groin Injuries Rate Among Soccer Players.

The effect of the Copenhagen Adduction Exercise on groin injuries rate among soccer players The Copenhagen adduction exercise is a body-weight exercise which mainly works the groin and hip Adductors. It has a large eccentric component, meaning the muscles are working whilst lengthening.

The purpose of this study is to investigate the effect of the Copenhagen adduction exercise on groin injuries among soccer players.

It hypothesized that Copenhagen adduction exercise has a beneficial effect in terms of groin injury prevention.

Study type Interventional Description of intervention(s) / exposure The intervention group will be instructed to include the Copenhagen adduction exercise into their warm up before training session (3 times per week) during one season (6 months).

Group sessions will be administered by an exercise physiologist and/ or athletic trainer and/ or soccer coaches and/ or strength and conditioning specialists and/ or physiotherapist.

Session attendance checklists will be used to assess or monitor adherence to the intervention.

The Copenhagen adduction exercise is a body-weight exercise which mainly works the groin and hip adductor. It has a large eccentric component, meaning the muscles are working whilst lengthening.

The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.

The Copenhagen Adduction exercise requires a partner who will hold the player's upper leg in an extended position nearly at the hip level of the partner, with one hand supporting the knee and the other upholding the ankle. Meanwhile, the player will lie on one side and support the body with the forearm on the ground and the top arm being placed along the body. Then, the player will elevate the trunk from the floor and raise the lower leg in a straight line. The player will repeat this for 3 seconds until the feet touch each other. This will be followed by slightly lowering the body just to the ground for 3 seconds until it touches the level of the foot.

It must be performed on both limbs. It is crucial to note that the most accurate performance of the exercise must avoid trunk bending. In terms of the training form, the frequency is three-two sessions per week while the repetition varies according to the different levels of the players ranging from 3-12 times in one-two sets.

Prevention Comparator / control treatment The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.

Eligibility Criteria:
Inclusion Criteria:

Soccer teams Amateur. Male . Training at least three times per week.

Exclusion Criteria:

History of lower extremity injury requiring medical attention in the past 6 months, or systemic diseases, cardiovascular disease, neurological disorders or bone fractures or surgery in the previous year.

Players who joined a participating team after the start of the trial will be excluded.
The Length of Uteroovarian Ligament and the Risk of Ovarian Torsion

Ovarian torsion is one of the gynecological emergency. This complication requires high clinical suspicion and early detection, to prevent permanent loss of ovarian function. The long uterine ovarian ligament could be a risk factor for ovarian torsion. We want to measure the uterine ovarian ligament length during routine laparoscopy/laparotomy and to compare the length between the torsion group and other non torsion patients

Female patient who are going to undergo laparoscopy/laparotomy for any gynecological reason will ask to participate. During the operation the uteroovarian ligament length will be measure by sterile ruler (calibrated plastic device 1 mm in diameter).

The length of uteroovarian ligament will compared between the patient who will diagnose with ovarian torsion (study group) and the other women (control group)

Eligibility Criteria:
Inclusion Criteria:

* Indication for gynecological operation
* hemodynamically stable

Exclusion Criteria:

* Ovarian torsion in the past
* History of pelvic inflammatory disease (PID)
Spinal Arthrodesis and Spinal Arthroplasty Database Study

To collect and organize data into a repository for future research.

To collect and organize data into a repository from the Principal Investigator's (H. Francis Farhadi, MD, PhD) patients who are undergoing spinal arthrodesis and/or spinal arthroplasty procedures at Ohio State University for future research, as yet to be identified. This comprehensive database of patients will allow for gathering of relevant information for potential future research use.

Eligibility Criteria:
Inclusion Criteria:

* Must have had or will undergo a spinal arthrodesis and/or spinal arthroplasty procedure at Ohio State University

Exclusion Criteria:

* N/A
Symbicort Rapihaler Therapeutic Equivalence Study

The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Asthma clinically diagnosed since at least 6 months.
* Lung function values measured ≥ 50% and ≤ 90% of predicted normal.
* Patients with reversible airway obstruction Daily use of inhaled steroids (any brand) for \>3 months.

Exclusion Criteria:

* Use of oral, rectal or parenteral steroids within 30 days prior to start of study.
* Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to start of randomised treatment.
* Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study.
Understanding the Sleep Apnea/Insomnia Interaction

Nearly half of all patients with obstructive sleep apnea have insomnia symptoms, and in some, but not all cases, these insomnia symptoms are caused by the obstructive sleep apnea. The purpose of this study is to find out what type of insomnia symptoms are caused by obstructive sleep apnea and therefore most likely to respond to obstructive sleep apnea treatment with continuous positive airway pressure (also known as CPAP) and if additional treatment with cognitive-behavioral therapy for insomnia is beneficial.


Eligibility Criteria:
Inclusion Criteria:

1. Sleep Apnea
2. Insomnia
3. Age \>18

Exclusion Criteria:

1. Sedative/psychoactive drug use recently
2. Other clinically significant sleep disorders
3. Previous treatment for obstructive sleep apnea (OSA)
4. Requires oxygen or bilevel PAP therapy
5. Clinically unstable medical condition
6. Recent shift work
7. Significant alcohol use
8. Other clinically significant causes of insomnia
9. Illicit drug use
10. Prescription stimulants
11. Safety restrictions
12. Unable to treat sleep apnea with positive airway pressure therapy
13. Communication barriers
14. Cognitive impairment
Effects of Eccentric Banded Leg Curls Versus Eccentric Cable Leg Curls Exercises in Cricket Players

Hamstring injuries are highly prevalent among cricket players, comprising 10% of all injuries in field-based team sports. Eccentric strength deficits and imbalances in muscle strength are linked to a higher risk of such injuries. Our randomized clinical trial aims to assess eccentric hamstring strength using eccentric banded leg curls and eccentric cable leg curl exercises, measured by the Nordbord device. This tool provides accurate measurements of eccentric hamstring strength, power, and endurance, crucial for injury prevention in athletes. Thirty-two male professional cricketers will participate, divided into two groups receiving different exercise plans. Each group will perform 15 reps in 3 sets with rest intervals, four times a week for four months. The Nordbord device will assess hamstring strength before and after the exercise plan. Statistical analysis will be done using SPSS V25, employing descriptive statistics for frequency distribution and inferential statistics such as t-tests to compare outcomes between treatment groups.

The present study aims to assess the effects of eccentric banded leg curls versus eccentric cable leg curls exercise on eccentric knee-flexor strength assessed with an instrumented Nordic hamstring device (Nordbord) after training in Cricket Players.

Eligibility Criteria:
Inclusion Criteria:

* Participants range in age from 14 to 35 years.
* Only male individuals are eligible for inclusion.
* Eligible participants include professional cricketers at domestic and international levels (U-16, U-19, or above), as well as recent additions to domestic cricket.
* Participants must have either good health or chronic lower extremity injuries impacting hamstring muscle strength.
* Willingness to provide informed consent is a prerequisite for study participation.

Exclusion Criteria:

* Individuals outside the age range of 14 to 35 years are excluded.
* Exclusion criteria include a medical history of neurological or musculoskeletal conditions impacting the lower extremities, such as nerve disorders or severe arthritis.
* Those with lower extremity injuries sustained within the previous two months are ineligible.
* Participants who have undergone lower extremity surgery within the past six months are not eligible.
* Exclusion applies to individuals taking medications that may impact muscle strength or neuromuscular function.
* Individuals who refuse to provide informed consent are not included in the study.
Opioid-induced Hyperalgesia After Remifentanil Infusion

Remifentanil is a rapid-acting opioid which has been widely used in pain treatment during surgery for the last 15 years 1. Remifentanil is rapidly eliminated (minutes) from the body after end of infusion, and this makes it easily manageable compared to other opioids. However, there are both experimental and clinical studies indicating that remifentanil, after end of infusion, triggers increased pain sensation and increased opioid consumption post-operatively. Increased post-operative opioid consumption should be avoided due to the adverse effects of these drugs (nausea/vomiting, pruritus, dizziness, fatigue and reduced respiratory rate). Thus, it's important to investigate relevant strategies to avoid the increased pain sensation (opioid-induced hyperalgesia = hypersensitivity to pain stimuli) after end of infusion of remifentanil after surgery. Several experimental and clinical trials have been conducted in this field. Ketamine has been shown to block this effect, but its adverse effect profile (i.a. hallucinations) makes it not suitable in normal clinical use. In a study of healthy volunteers, it has been demonstrated that parecoxib (a COX-2 selective NSAID) can prevent remifentanil-induced hyperalgesia. Our group has previously shown that a relatively COX-1 selective NSAID (ketorolac) can prevent hyperalgesia in an experimental pain model.

This is of interest since NSAIDs are frequently administered as premedication before surgery. There are several disadvantages associated with the use of COX-2 inhibitors, e.g. the risk of myocardial infarction after long-term use (\> 1 year), and potentially reduced bone healing after orthopedic surgery. However, this has not been shown with short-term use (days/week). The disadvantages associated with the use of e.g. ketorolac (a COX-1 inhibitor) are i.a. increased bleeding tendency, which is unfavourable for the surgeon, and increased risk of gastric ulcer. Therefore, it is of interest to investigate other ways of preventing opioid-induced hyperalgesia. In a recent animal study it has been shown that gradual dose reduction of remifentanil (vs. abrupt withdrawal of a relatively high remifentanil dose) can prevent the development of hyperalgesia after end of infusion. In this study we will i.a. investigate whether this is also the case in humans. In this new model, the study participants will get remifentanil infusion with two different dose reduction regimes: gradual reduction or abrupt withdrawal.


Eligibility Criteria:
Inclusion Criteria:

* Male
* Age 18-60
* Body mass index 17-30
* Healthy volunteers

Exclusion Criteria:

* Use of medication; alternative medicine
* Substance abuse
* Allergies towards medication used in the study
* Participation in other clinical studies the previous 6 months
Electrical Activity of the Diaphragm and Respiratory Mechanics During NAVA

Protective ventilatory strategy should be applied to reduce both ventilator-induced lung injury (VILI) and ventilator-induced diaphragm dysfunction (VIDD) after Lung Transplantation (LTx). Neurally Adjusted Ventilatory Assist (NAVA) is an assisted ventilation mode in which respiratory support is coordinated by the electrical activity of the diaphragm (EAdi). Aim of the study is to assess the physiological relationship between neural respiratory drive as assessed by EAdi and tidal volume, driving pressure and mechanical power, at different levels of ventilatory assist, in the absence of pulmonary vagal afferent feedback.

Lung transplantation (LTx) is an important treatment option for select patients with end-stage pulmonary disease. In the early period following LTx a protective ventilatory strategy should be applied to reduce both ventilator-induced lung injury (VILI) and ventilator-induced diaphragm dysfunction (VIDD) after Lung Tranplantation (LTx). Neurally Adjusted Ventilatory Assist (NAVA) is an assisted ventilation mode in which neural inspiratory activity is monitored through the continuous recording of electrical activity of the diaphragm (EAdi) and then used to coordinate the respiratory support delivered by the ventilator.

NAVA, because of its intrinsic properties (proportionality between respiratory drive and level of assist, prevention of diaphragm atrophy), could allow the aforementioned ventilatory strategy, however it may require the integrity of the pulmonary vagal afferent feedback in order to avoid volutrauma. So, the aim of the study is the evaluation of the physiological relationship between EAdi and tidal volume, driving pressure and mechanical power, at different levels of ventilatory assist, in the absence of pulmonary vagal afferent feedback, in early post-operative period after LTx.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 y.o.
* Admission to ICU for post-operative monitoring after LTx
* Presence of spontaneous breathing activity
* Sedation titrated to a target RASS between 0 and -2
* Written informed consent obtained

Exclusion Criteria:

* Contraindication to nasogastric tube insertion (gastroesophageal surgery in the previous 3 months, gastroesophageal bleeding in the previous 30 days, history of esophageal varices, facial trauma)
* Increased risk of bleeding with nasogastric tube insertion, due to severe coagulation disorders and severe thrombocytopenia ( i.e., INR \> 2 and platelets count \< 70.000/mm3)
* Severe hemodynamic instability (noradenaline \> 0.3 μg/kg/min and/or use of vasopressin)
* Postoperative extracorporeal respiratory support (ECMO)
* Pre-operative reconditioning of the transplanted lungs by means of ex-vivo lung perfusion (EVLP)
* Lung retransplantation
* Failure to obtain a stable EAdi signal
Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin

This randomized pilot trial studies how well fat emulsion works in preventing hypersensitivity reactions in patients with cancer receiving carboplatin or oxaliplatin. Giving lipids before chemotherapy may prevent some drug reactions from carboplatin or oxaliplatin.

PRIMARY OBJECTIVES:

I. To determine if the infusion of a lipid emulsion before each dose of chemotherapy appears to prevent carboplatin and oxaliplatin hypersensitivity reactions in high-risk patients.

II. To explore if lipid infusions modulate a well-established panel of mediators of hypersensitivity reactions and if these mediators appear to predict reactions.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive fat emulsion intravenously (IV) immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.

GROUP II: Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.

Eligibility Criteria:
Inclusion Criteria:

* Advanced, incurable cancer
* 7th or later cycle of intravenous carboplatin or oxaliplatin infusion planned or 4 months after the first cycle of agent (whichever is of longer duration) =\< 30 days after registration
* Anticipated 2 or more subsequent chemotherapy infusions of either carboplatin or oxaliplatin at the time of study registration; NOTE: the dose of carboplatin or oxaliplatin, choice of other chemotherapy, and other ancillary treatment, such as antiemetics, will be left to the discretion of the treating healthcare provider
* Willing to provide mandatory blood and urine specimens for correlative research; NOTE: can be waived with permission of study chair (documentation such as an email must be provided)
* Serum creatinine =\< 1.5 times the institutional upper limit of normal (ULN); NOTE: can be waived with permission of study chair (documentation such as an email must be provided)
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 3 x the upper limit of normal
* Triglycerides \< 500 mg/dL
* Alkaline phosphatase =\< 3 x the institutional upper limit of normal

Exclusion Criteria:

* Concurrent liposomal doxorubicin or any other liposomal agent
* Prior carboplatin or oxaliplatin hypersensitivity reaction
* Taking aspirin, nonsteroidal anti-inflammatory agents, or zileuton =\< 7 days prior to registration; NOTE: can be waived with permission of study chair (documentation such as an email must be provided)
* Allergy to egg or egg byproducts